Tumor receptor imaging

Journal of Nuclear Medicine

Volumn 49, Issue SUPPL.6, 2008, Pages

  Mankoff, David A ^a,b,c   Link, Jeanne M ^a   Linden, Hannah M ^a,b   Sundararajan, Lavanya ^a,b   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c Department of Oral Medicine   (United States)

Author keywords

Imaging; Receptors; Tumors

Indexed keywords

11 BETA METHOXY 17 ALPHA IODOVINYLESTRADIOL I 123; 16 BETA FLUORO 5 ALPHA DIHYDROTESTOSTERONE F 18; 2 (2 FLUOROETHOXY) 5 METHYLBENZAMIDE F 18; 21 FLUORO 16 ALPHA ETHYL 19 NORPROGESTERONE F 18; AROMATASE INHIBITOR; CETUXIMAB; DTPA EGF IN 111; DTPA TRASTUZUMAB IN 111; ESTRADIOL; ESTROGEN RECEPTOR; FLUTAMIDE; GALACTO RGD F 18; GEFINITIB C 11; GROWTH FACTOR RECEPTOR; LEVOTHYROXINE; N (4 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2 H YL)BUTYL); PENTETREOTIDE IN 111; POLYLACTIC ACID NANOPARTICLE TRASTUZUMAB; PROGESTERONE RECEPTOR; SOMATOSTATIN RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; TRACER; TRASTUZUMAB; UNINDEXED DRUG;

BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; ECHOGRAPHY; HUMAN; LIGAND BINDING; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER;

ANIMALS; HUMANS; LIGANDS; MICE; NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, GROWTH FACTOR; RECEPTORS, STEROID; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 46749092981     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.045963     Document Type: Review

References (188)

1. Kaklamani V, O'Regan RM. New targeted therapies in breast cancer. Semin Oncol. 2004;31(2, suppl 4):20-25.
2. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46(12, suppl):2884-2888.
3. Sledge GJ, McGuire W. Steroid hormone receptors in human breast cancer. Adv Cancer Res. 1983;38:61-75.
4. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23:2445-2459.
5. 18F] fluorodeoxyglucose and beyond. Clin Cancer Res. 2007;13:3460-3469.
6. Mankoff DA, O'Sullivan F, Barlow WE, Krohn KA. Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol. 2007;14:398-405.
7. Krohn KA. The physical chemistry of ligand-receptor binding identifies some limitations to the analysis of receptor images. Nucl Med Biol. 2001;28:477-483.
8. Krohn KA, Link JM. Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nucl Med Biol. 2003;30:819-826.
9. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-629.
10. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(suppl 4):S3-S8.
11. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79-94.
12. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2007;5:568-621.
13. Campbell FC, Elston CW, Blamey RW, et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1981;1:1317-1319.
14. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17:1573-1576.
15. Katzenellenbogen BS, Fang H, Ince BA, et al. Estrogen receptors: ligand discrimination and antiestrogen action. Breast Cancer Res Treat. 1993;27:17-26.
16. Stein RA, McDonnell DP. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr Relat Cancer. 2006;13(suppl 1):S25-S32.
17. Hammond G. Steroid hormone action. In: Parker M, ed. Extracellular Steroid-Binding Proteins. New York, NY: Oxford University Press; 1993:210.
18. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994;74:1601-1606.
19. Cigler T, Goss PE. Breast cancer adjuvant endocrine therapy. Cancer J. 2007;13:148-155.
20. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.
21. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21:28-34.
22. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol. 2001;77:139-147.
23. Reed MJ, Purohit A. Aromatase regulation and breast cancer. Clin Endocrinol (Oxf). 2001;54:563-571.
24. Pan CC, Woolever CA, Bhavnani BR. Transport of equine estrogens: binding of conjugated and unconjugated equine estrogens with human serum proteins. J Clin Endocrinol Metab. 1985;61:499-507.
25. Petra P. The plasma sex steroid binding protein (SBP or SBHG): a critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol. 1991;40:735-753.
26. 18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol. 1999;26:123-130.
27. 18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999;26:905-913.
28. Plymate SR, Namkung PC, Metej LA, Petra PH. Direct effect of plasma sex hormone binding globulin (SHBG) on the metabolic clearance rate of 17 betaestradiol in the primate. J Steroid Biochem. 1990;36:311-317.
29. Bolt HM. Metabolism of estrogens: natural and synthetic. Pharmacol Ther. 1979;4:155-181.
30. Fink BJ, Christensen MS. Bioavailability of oestradiol and oestriol administered orally to oophorectomized women. Maturitas. 1981;3:289-294.
31. Scharl A, Beckman MW, Artwohl JE, Kullander S, Holt JA. Rapid liver metabolism, urinary and biliary excretion, and enterohepatic circulation of 16alpha-radioiodio-17beta-estradiol. Int J Radiat Oncol Biol Phys. 1991;21:1235-1240.
32. White CM, Ferraro-Borgida MJ, Fossati AT, et al. The pharmacokinetics of intravenous estradiol: a preliminary study. Pharmacotherapy. 1998;18:1343-1346.
33. Katzenellenbogen J. The pharmacology of steroid radiopharmaceuticals: specific and non-specific binding and uptake selectivity. In: Nunn A, ed. Radiopharmaceuticals: Chemistry and Pharmacology. New York, NY: Marcel Dekker; 1992:297-331.
34. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276-285.
35. Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr. 2000;27:135-145.
36. Baselga J, Cortes J. Epidermal growth factor receptor pathway inhibitors. Cancer Chemother Biol Response Modif. 2005;22:205-223.
37. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
38. Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts. Hematol Oncol Clin North Am. 2007;21:395-407.
39. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227s-4232s.
40. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001;28:291-304.
41. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev. 1990;11:578-610.
42. Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Ther. 2001;8:333-344.
43. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 2000;18:3748-3757.
44. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer. 2001;8:191-195.
45. de Herder WW, Kwekkeboom DJ, Feelders RA, et al. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary. 2006;9:243-248.
46. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
47. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247.
48. 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging. 2003;30:117-122.
49. Katzenellenbogen JA. The development of gamma-emitting hormone analogs as imaging agents for receptor-positive tumors. Prog Clin Biol Res. 1981;75B:313-327.
50. Katzenellenbogen JA, Hsiung HM, Carlson KE, McGuire WL, Kraay RJ, Katzenellenbogen BS. Iodohexestrols. II. Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives, in vitro and in vivo. Biochemistry. 1975;14:1742-1750.
51. Katzenellenbogen JA. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med. 1995;36(6, suppl):8S-13S.
52. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212-1221.
53. 18F]fluoroestradiols: selective receptor-based PET imaging agents. Int J Rad Appl Instrum B. 1992;19:363-374.
54. Lim JL, Zheng L, Berridge MS, Tewson TJ. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol. Nucl Med Biol. 1996;23:911-915.
55. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol. 1997;24:341-348.
56. Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med. 1998;42:8-17.
57. 18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum A. 1987;14:15-25.
58. Bonasera TA, O'Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med. 1996;37:1009-1015.
59. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344-350.
60. 18F]-radiolabeled hydroxyflutamide derivatives. Bioorg Med Chem. 2005;13:6195-6205.
61. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373.
62. Parent EE, Carlson KE, Katzenellenbogen JA. Synthesis of 7alpha-(fluoromethyl) dihydrotestosterone and 7alpha-(fluoromethyl) nortestosterone, structurally paired androgens designed to probe the role of sex hormone binding globulin in imaging androgen receptors in prostate tumors by positron emission tomography. J Org Chem. 2007;72:5546-5554.
63. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol. 2006;33:371-380.
64. Liu A, Carlson KE, Katzenellenbogen JA. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor: potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem. 1992;35:2113-2129.
65. 18F]fluoro-16 α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med. 1991;32:1532-1537.
66. 18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol. 1994;21:941-952.
67. Zhou D, Carlson KE, Katzenellenbogen JA, Welch MJ. Bromine- and iodine-substituted 16alpha, 17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J Med Chem. 2006;49:4737-4744.
68. 77Br]bromoestradiol-17 β: a high specific-activity, gamma-emitting tracer with uptake in rat uterus and uterus and induced mammary tumors. J Nucl Med. 1981;22:42-47.
69. 125I]iodoestradiol-17 β. J Nucl Med. 1982;23:420-424.
70. Rijks LJ, Busemann Sokole E, Stabin MG, de Bruin K, Janssen AG, van Royen EA. Biodistribution and dosimetry of iodine-123-labelled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging. Eur J Nucl Med. 1998;25:40-47.
71. 123I]iodoestradiol and its interaction with the estrogen receptor in vivo and in vitro. J Nucl Med. 1989;30:209-215.
72. 18F]fluorine substitution at the 16alpha-position of fulvestrant (Faslodex; ICI 182,780). Nucl Med Biol. 2004;31:691-698.
73. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids. 2002;67:765-775.
74. Cummins CH. Radiolabeled steroidal estrogens in cancer research. Steroids. 1993;58:245-259.
75. 18F]fluoro-17 beta-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters. J Cereb Blood Flow Metab. 1995;15:301-311.
76. Moresco RM, Scheithauer BW, Lucignani G, et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun. 1997;18:606-615.
77. 18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001;42:679-684.
78. Bennink RJ, Rijks LJ, van Tienhoven G, Noorduyn LA, Janssen AG, Sloof GW. Estrogen receptor status in primary breast cancer: iodine 123-labeled cis-11beta-methoxy-17alpha-iodovinyl estradiol scintigraphy. Radiology. 2001;220:774-779.
79. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
80. Mankoff DA, Peterson LM, Petra PH, et al. Factors affecting the level and heterogeneity of uptake of F-18-fluoroestradiol (FES) in patients with estrogen receptor-positive breast cancer [abstract]. J Nucl Med. 2002;43:286-287.
81. 18F- fluoroestradiol. J Nucl Med. 2008;49:367-374.
82. 18F]fluoro-17 β-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526-1531.
83. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
84. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933-939.
85. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799.
86. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584-2589.
87. Spataro V, Price K, Goldhirsch A, et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol. 1992;3:733-740.
88. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803.
89. 18F- fluoroestradiol positron emission tomography (FES PET) measures estrogen receptor binding during endocrine therapy. Breast Cancer Res Treat. 2005;94(suppl 1):5088.
90. Tsuchida T, Okazawa H, Mori T, et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET: influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol. 2007;34:205-210.
91. Yoshida Y, Kurokawa T, Sawamura Y, et al. The positron emission tomography with F-18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol. 2007;104:764-766.
92. Low MJ. Clinical endocrinology and metabolism: the somatostatin neuroendocrine system - physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab. 2004;18:607-622.
93. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors: peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007;21:111-129.
94. Ferone D, Semino C, Boschetti M, Cascini GL, Minuto F, Lastoria S. Initial staging of lymphoma with octreotide and other receptor imaging agents. Semin Nucl Med. 2005;35:176-185.
95. 111indium- octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2007;81:167-174.
96. Rostomily RC, Elias M, Deng M, et al. Clinical utility of somatostatin receptor scintigraphic imaging (Octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 2006;28:305-312.
97. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242-244.
98. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115-1122.
99. Sprague JE, Peng Y, Sun X, et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10:8674-8682.
100. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:69-85.
101. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213-221.
102. 111In-pentetreotide. J Nucl Med. 2001;42:1134-1138.
103. 11C-labelled peptides in tumour diagnosis with PET. Eur J Nucl Med Mol Imaging. 2004;31:1653-1657.
104. 18F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004;10:3593-3606.
105. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2006;33:823-830.
106. Junik R, Drobik P, Malkowski B, Kobus-Blachnio K. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET). Adv Med Sci. 2006;51:66-68.
107. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.
108. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas - a prospective study. Ann Intern Med. 1996;125:26-34.
109. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853-858.
110. Hillel PG, van Beek EJ, Taylor C, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol. 2006;61:579-587.
111. Scarsbrook AF, Ganeshan A, Statham J, et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics. 2007;27:455-477.
112. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
113. Losa M, Magnani P, Mortini P, et al. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med. 1997;24:728-773.
114. 111Inpentetreotide: is there evidence of somatostatin receptor downregulation? J Nucl Med. 2006;47:354-359.
115. Martins RG, Rajendran JG, Capell P, Byrd DR, Mankoff DA. Medullary thyroid cancer: options for systemic therapy of metastatic disease? J Clin Oncol. 2006;24:1653-1655.
116. Bushnell D. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:335-336.
117. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123-132.
118. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.
119. 90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147-156.
120. 68Ga]- DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222-227.
121. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem. 1999;10:502-511.
122. 111In-DTPA-human epidermal growth factor: an Auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006;47:1023-1031.
123. 111In for imaging human breast cancer. J Nucl Med. 2000;41:903-911.
124. 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol. 2001;28:359-374.
125. 18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-yl]-amide moiety: an EGFR putative irreversible inhibitor. Appl Radiat Isot. 2007;65:1140-1151.
126. Fernandes C, Oliveira C, Gano L, Bourkoula A, Pirmettis I, Santos I. Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer. Bioorg Med Chem. 2007;15:3974-3980.
127. 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci. 1999;65:165-174.
128. 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol. 2006;8:262-277.
129. Shaul M, Abourbeh G, Jacobson O, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem. 2004;12:3421-3429.
130. VanBrocklin HF, Lim JK, Coffing SL, et al. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem. 2005;48:7445-7456.
131. Bogdanov A Jr, Kang HW, Querol M, Pretorius PH, Yudina A. Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo. Bioconjug Chem. 2007;18:1123-1130.
132. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850-858.
133. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339-4348.
134. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
135. Pnwar P, Iznaga-Escobar N, Mishra P, et al. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther. 2005;4:854-860.
136. 99mTc-chelating mercaptoacetylglycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging. 2007;34:722-733.
137. 111In-benzyl-DTPA- ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47:846-853.
138. Dorow DS, Cullinane C, Conus N, et al. Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. Eur J Nucl Med Mol Imaging. 2006;33:441-452.
139. Meenakshi A, Kumar RS, Ganesh V, Kumar NS. Preliminary study on radioimmunodiagnosis of experimental tumor models using technetium-99m-labeled anti-C-erbB-2 monoclonal antibody. Tumori. 2002;88:507-512.
140. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65:1471-1478.
141. 111In- trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51-58.
142. Wiercioch R, Balcerczak E, Byszewska E, Mirowski M. Uptake of radiolabelled Herceptin by experimental mammary adenocarcinoma. Nucl Med Rev Cent East Eur. 2003;6:99-103.
143. 111Indium- trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046-2051.
144. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med. 1999;40:768-775.
145. Schillaci O, Danieli R, Picardi V, Bagni O, Di Loreto M, Scopinaro F. Immunoscintigraphy with a technetium-99m labelled anti-epithelial growth factor receptor antibody in patients with non-small cell lung cancer. Anticancer Res. 2001;21:3571-3574.
146. 18F-FDG PET. J Nucl Med. 2006;47:793-796.
147. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
148. 111In- labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357-1368.
149. 89Zf-trastuzumab for clinical HER2 immunoPET imaging [abstract]. J Clin Oncol. 2007;25(18S):140s.
150. Linden HM, Krohn KA, Livingston RB, Mankoff DA. Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response? Clin Cancer Res. 2006;12:5608-5610.
151. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659-5667.
152. Becker A, Hessenius C, Licha K, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol. 2001;19:327-331.
153. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt. 2001;6:122-133.
154. Licha K, Hessenius C, Becker A, et al. Synthesis, characterization, and biological properties of cyanine-labeled somatostatin analogues as receptor-targeted fluorescent probes. Bioconjug Chem. 2001;12:44-50.
155. Shen D, Liang K, Ye Y, Tetteh E, Achilefu S. Modulation of nuclear internalization of Tat peptides by fluorescent dyes and receptor-avid peptides. FEBS Lett. 2007;581:1793-1799.
156. Johansson LO, Bjornerud A, Ahlstrom HK, Ladd DL, Fujii DK. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging. 2001;13:615-618.
157. Adams KE, Ke S, Kwon S, et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt. 2007;12:024017.
158. Gee MS, Upadhyay R, Bergquist H, Weissleder R, Josephson L, Mahmood U. Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment. Int J Cancer. 2007;121:2492-2500.
159. Achilefu S. Lighting up tumors with receptor-specific optical molecular probes. Technol Cancer Res Treat. 2004;3:393-409.
160. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003;63:2723-2727.
161. Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007;13:95-99.
162. Liu J, Li J, Rosol TJ, Pan X, Voorhees JL. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol. 2007;52:4739-4747.
163. Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther. 2007;6:1230-1238.
164. Winnard P Jr, Raman V. Real time non-invasive imaging of receptor-ligand
165. Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res. 2007;13:2936-2945.
166. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005;5:709-711.
167. Hilger I, Leistner Y, Berndt A, et al. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol. 2004;14:1124-1129.
168. Hsu ER, Anslyn EV, Dharmawardhane S, et al. A far-red fluorescent contrast agent to image epidermal growth factor receptor expression. Photochem Photobiol. 2004;79:272-279.
169. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 2003;63:7870-7875.
170. Keese M, Magdeburg RJ, Herzog T, et al. Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. J Biol Chem. 2005;280:27826-27831.
171. Arwert E, Hingtgen S, Figueiredo JL, et al. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res. 2007;67:7335-7342.
172. Funovics MA, Kapeller B, Hoeller C, et al. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging. 2004;22:843-850.
173. Copland JA, Eghtedari M, Popov VL, et al. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol. 2004;6:341-349.
174. Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol. 1999;26:481-490.
175. Belousova N, Harris R, Zinn K, et al. Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette. Mol Pharmacol. 2006;70:1488-1493.
176. Rogers BE, Chaudhuri TR, Reynolds PN, Della Manna D, Zinn KR. Noninvasive gamma camera imaging of gene transfer using an adenoviral vector encoding an epitope-tagged receptor as a reporter. Gene Ther. 2003;10:105-114.
177. Yang D, Han L, Kundra V. Exogenous gene expression in tumors: noninvasive quantification with functional and anatomic imaging in a mouse model. Radiology. 2005;235:950-958.
178. Furukawa T, Lohith TG, Takamatsu S, Mori T, Tanaka T, Fujibayashi Y. Potential of the FES-hERL PET reporter gene system: basic evaluation for gene therapy monitoring. Nucl Med Biol. 2006;33:145-151.
179. Takamatsu S, Furukawa T, Mori T, Yonekura Y, Fujibayashi Y. Noninvasive imaging of transplanted living functional cells transfected with a reporter estrogen receptor gene. Nucl Med Biol. 2005;32:821-829.
180. 123I]iodovinylestradiol is a promising radioligand for estrogen receptor imaging in human breast cancer. Nucl Med Biol. 1997;24:65-75.
181. Tu Z, Xu J, Jones LA, et al. Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J Med Chem. 2007;50:3194-3204.
182. 11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2006;16:4102-4106.
183. 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med. 2005;46:1881-1888.
184. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
185. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004;64:8009-8014.
186. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999;81:658-665.
187. 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-1397.
188. Montet X, Weissleder R, Josephson L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug Chem. 2006;17:905-911.